真正杀死中年人的，不是工作时间的长短，而是"无法恢复"。 作者： 李佩珊 郑淯心 封图：华大集团官网 最值得重视的变化，我认为是"身体与自我关系的异化"。 过去我们说"身体是革命的本钱"，那是把身体当作工具。但现在，很多人把身体当成了"敌人"， 或者说，当成了一个需要被"征服"的对象。我们不再倾听身体的声音，而是用各种指标、KPI 去"审判"身体。工作有KPI，健身有KPI，甚至连睡眠都要追求"深度睡眠时长"的KPI。 3月24日，知名教育博主、志愿填报名师张雪峰因心源性猝死抢救无效去世，终年41岁。 据网传张雪峰朋友圈截图，他的最后一条朋友圈发布于3月22日，是一张7公里的跑步打卡图，图 中同时显示其当月累计跑步72公里。2023年6月，张雪峰也曾因过度劳累、胸闷心悸住院。此 后，他开始跑步、打卡、记录里程。身体亮过一次"红灯"之后，选择用更严格的方式"管理"自 己，在今天的中年人里并不罕见。 2022年，华为高管丁耘突发离世，享年53岁。华友会主席兼创始人俞渭华在纪念文章中提到，丁 耘生前热爱跑步，出事前曾完成28公里长跑。更早的案例来自美国。1977年，美国作家 Jim Fixx 出版《跑步全书》，被认 ...

| 股东名称 | 是否为控股 股东或第一 大股东及其 | 本次解除质 押股份数量 | 占其所持股 份比例 | 占公司 总股本 | 质押起始 日期 | 质押解除日 期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 一致行动人 | （股） | | 比例 | | | | | 深圳华大基因 | | | | | | | 珠海华润银行 | | 科技有限公司 | 是 | 7,000,000 | 5.62% | 1.67% | 2024/3/13 | 2026/3/19 | 股份有限公司 | | | | | | | | | 深圳分行 | （一）本次股份解除质押的基本情况 （二）本次股份质押的基本情况 证券代码：300676 证券简称：华大基因 公告编号：2026-014 深圳华大基因股份有限公司 关于控股股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 深圳华大基因股份有限公司（以下简称公司或上市公司）近日收到公司控股股 东深圳华大基因科技有限公司（以下简称华大控股 ...

证券代码：300676 证券简称：华大基因 公告编号：2026-013 深圳华大基因股份有限公司 关于控股股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 深圳华大基因股份有限公司（以下简称公司或上市公司）近日收到公司控股股 东深圳华大基因科技有限公司（以下简称华大控股）的通知，获悉华大控股将其持 有的部分公司股份办理了解除质押及再质押。现将具体情况公告如下： 一、控股股东及其一致行动人部分股份解除质押及再质押的基本情况 | 股东名称 | 是否为控股 股东或第一 | | 本次解除质 押股份数量 | 占其所持股 | 占公司 总股本 | 质押起始 | 质押解除日 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 | | | 份比例 | | 日期 | 期 | | | | 一致行动人 | | （股） | | 比例 | | | 兴业银行股份 | | 深圳华大基因 科技有限公司 | 是 | | 5,500,000 | 4.42% | 1.31 ...

Investment Rating - The industry investment rating is "Buy" [1] Core Insights - The report highlights the rapid growth of synthetic biology, with a significant increase in the number of synthetic biology companies in Beijing's Changping District, which has surged nearly 70% compared to the same period last year, reaching a total of 146 companies [9] - The establishment of the world's largest pilot transformation platform by Huaxi Biological in Tianjin, which has a total investment of several billion yuan and spans 40,000 square meters, is a key development in the industry [10] - The National Development and Reform Commission has issued the "14th Five-Year Plan for the Development of the Bioeconomy," indicating a trillion-yuan market potential in the bioeconomy sector [4] Market Dynamics - The Huaxi Synthetic Biology Index decreased by 0.49% to 1271.82 during the week of February 24-27, 2026, underperforming compared to the Shanghai Composite Index, which rose by 1.98% [5] - The report notes that the synthetic biology sector is experiencing a wave of technological advancements and increased investment, with nearly 100 companies completing new financing rounds since 2025 [33] Company Developments - Huaxi Biological's pilot platform has already undertaken over 30 biological manufacturing projects, facilitating the transition from laboratory-scale to commercial-scale production [10] - The report mentions that Lif Biological's PEF (polyethylene furanoate) has received approval for food contact use, marking a significant step for bio-based materials in the food packaging sector [24] - Watson Biological has announced a 450 million yuan investment to establish a fund focused on synthetic biology, with a target size of 1 billion yuan [25] Industry Financing - The report indicates that financing in the synthetic biology sector is accelerating, with companies like Rhein Biological and EcoviaBio completing multiple rounds of financing to expand their production capabilities [33][34] - Rhein Biological is focusing on two main development directions: enhancing its core business and providing industrialization services for external synthetic biology products [34]

Investment Rating - The industry investment rating is "Buy" [1] Core Insights - The report highlights the rapid growth of synthetic biology, with a significant increase in the number of synthetic biology companies in Beijing's Changping District, which has surged nearly 70% compared to the same period last year, reaching a total of 146 companies [9] - The establishment of the world's largest pilot transformation platform by Huaxi Biological in Tianjin, which has a total investment of several billion yuan and spans 40,000 square meters, is a key development in the industry [10] - The "14th Five-Year Plan" for the development of the bio-economy has been issued by the National Development and Reform Commission, indicating a trillion-yuan market potential in the bio-economy sector [4] Market Dynamics - The Huaxi Synthetic Biology Index decreased by 0.49% to 1271.82 during the week of February 24-27, 2026, underperforming compared to the Shanghai Composite Index, which rose by 1.98% [5] - The report notes that the synthetic biology sector is experiencing a biotechnology revolution, providing innovative solutions to major challenges such as health, climate change, and food security [4] Company Developments - The report mentions that Watson Bio has established a 450 million yuan industry fund focused on synthetic biology, with a target size of 1 billion yuan [25] - Jin Dan Technology announced an additional investment of approximately 148 million yuan in its 75,000-ton annual production project for polylactic acid, bringing the total investment to 1.03 billion yuan [26] - The report also highlights the successful commercialization of products such as mannitol and alonose by companies like Weiyuan Synthetic [9] Industry Financing - The report indicates that financing in the synthetic biology sector is accelerating, with nearly 100 companies completing new financing rounds since 2025 [33] - EcoviaBio completed a Series B financing round to expand its production capacity for gamma-polyglutamic acid, a biodegradable material [34] - Verley, a precision fermentation company, successfully completed a $38 million Series A financing, marking a significant step towards commercializing precision fermentation [34]

Group 1: Company Overview and Business Strategy - Shenzhen BGI Genomics Co., Ltd. focuses on leveraging its long-term industry resources and technological barriers to advance in big data intelligent applications, particularly in vertical fields [3] - The company has accumulated a vast amount of high-quality multi-omics data resources over 20 years, which serves as a solid foundation for building its core competitive advantage in intelligent applications [3] - BGI Genomics aims to expand its business structure by enhancing both B-end (institutional) and C-end (individual consumer) services, establishing a dual-driven development model [4][5] Group 2: Market Position and Client Structure - The B-end business is the core revenue pillar, serving over 2,400 hospitals in China, with more than 1,000 utilizing localized testing solutions [5] - The company has completed over 100 technology transfer projects in 36 countries, enhancing its international B-end market share [5] - C-end business focuses on proactive health management, with a product matrix of over 30 offerings, including the i99 health management system and various genetic screening tests [6] Group 3: Innovation and Product Development - BGI Genomics has developed the GeneT multi-modal model for genetic testing, which has been clinically trialed in several top-tier hospitals across China [3] - The company is actively adapting to the shift towards value-based healthcare, emphasizing the importance of innovative testing products with clinical value and compliance advantages [4] - Future product strategies will focus on non-invasive prenatal testing (NIPT) and whole genome sequencing in overseas markets, particularly in regions with high birth rates [8] Group 4: Response to Aging Population and Chronic Disease Management - The company is addressing the growing demand for chronic disease management among the elderly, focusing on personalized health management solutions [10] - BGI Genomics has launched genetic risk assessment tests for Alzheimer's disease and other chronic conditions, integrating multi-omics data for comprehensive health management [10] - The company aims to build a differentiated and scalable chronic disease prevention system, emphasizing prevention over treatment [10] Group 5: Localization and Global Expansion - BGI Genomics is implementing a long-term strategy of "IVD + localization," transitioning from traditional external testing services to a dual-driven model of "equipment + reagents + services" [11] - The company has deployed localized solutions in over 1,000 hospitals across China and is expanding its global footprint through local partnerships and technology transfer [11] - The focus on localized services is expected to enhance the company's operational efficiency and revenue stability, with the localized business segment generating 1.124 billion yuan in revenue in the first three quarters of 2025 [11] Group 6: Risks and Market Considerations - The company's future performance is subject to uncertainties related to the application of innovative technologies and product development timelines [12] - Investors are advised to consider the potential volatility in stock prices due to rapid advancements in technology and market dynamics [12]

Group 1 - The core point of the article indicates that the precision medicine sector experienced a decline of 0.4% on February 26, with BGI Genomics leading the drop [1] - The Shanghai Composite Index closed at 4146.63, down 0.01%, while the Shenzhen Component Index closed at 14503.79, up 0.19% [1] - The precision medicine sector saw a net outflow of 512 million yuan from major funds, while retail investors contributed a net inflow of 325 million yuan [1] Group 2 - The article provides a summary of the fund flow within the precision medicine sector, highlighting a net inflow of 187 million yuan from speculative funds [1] - Detailed fund flow data for individual stocks in the precision medicine sector is mentioned, although specific stock details are not provided in the summary [1]

Core Insights - The article highlights the rapid growth and development of China's artificial intelligence (AI) industry, showcasing significant user adoption and innovation across various sectors [3][4][14][24][31]. Group 1: AI Industry Growth - By the end of 2025, China's generative AI user base is projected to reach 602 million, a 141.7% increase from the end of 2024, with a penetration rate of 42.8%, up 25.2 percentage points year-on-year [3]. - The AI industry in Beijing has surpassed 2,400 companies, including 46 listed firms and 36 unicorns, accounting for over half of the national total [4]. - Shanghai's AI industry is expected to exceed 550 billion yuan in scale by the end of 2025, with a year-on-year growth rate of over 30% [14]. Group 2: Key Players and Innovations - Major companies leading the AI sector include ByteDance, Baidu, and Huawei, focusing on areas such as large models, AI algorithms, and smart driving [5][24]. - Shenzhen has seen a 22.6% year-on-year growth in its core AI industry, with a total scale reaching 368.5 billion yuan in 2024, indicating a shift towards source innovation [24]. - Hangzhou's AI industry is projected to grow from 300 billion yuan in 2023 to 399 billion yuan in 2024, with 84 listed companies and 10 unicorns by the end of 2025 [31]. Group 3: Data and Infrastructure - Beijing has registered 123 large model products and established a data foundation with over 150 petabytes of data [4]. - Shanghai has completed 137 registrations for generative AI services, building a workforce of 300,000 in the AI sector [14]. - Shenzhen's AI industry encompasses a full range of the supply chain, from chips to applications, with 2,887 related enterprises [24].

Core Insights - The integration of biotechnology and information technology has reached a critical point in 2025, with a focus on redefining the efficiency and boundaries of gene testing through artificial intelligence [2] - The launch of Genos, a foundational model trained on 636 high-quality genomes, and GeneT, a clinical application tool, marks a significant advancement in understanding genomic data [2][3] - The company aims to make precision medicine more accessible and convenient, particularly in cancer prevention and screening [4] Group 1: Technological Advancements - Genos has the capability to analyze non-coding regions of the genome, which are crucial for understanding many life regulatory mechanisms, using long-context analysis [2] - GeneT connects knowledge bases with sequencing data to assist in generating professional diagnostic recommendations and reports, enhancing the efficiency of gene data interpretation [3] - The introduction of the "华消宁" testing product allows for risk assessment of five types of digestive system cancers using just 20 milliliters of peripheral blood, demonstrating a significant technological evolution [7][8] Group 2: Public Health Initiatives - A community project in Harbin, covering 2.4 million residents, utilizes a self-sampling method for fecal DNA methylation testing, simplifying the cancer screening process [5] - As of July 2025, over 800,000 appointments have been made for this project, indicating the feasibility of large-scale cancer early screening when technology is accessible and cost-effective [6] - The company has invested in automation tools, such as the SIRO high-throughput detection AI, to streamline the entire process from sample receipt to report generation [10] Group 3: Response to Public Health Challenges - The emergence of new infectious diseases, such as local cases of chikungunya and Nipah virus outbreaks, highlights the importance of biosecurity [11][12] - The company has established a comprehensive technical system that includes sequencing platforms and rapid testing kits to respond quickly to public health events [13] - International collaborations aim to build localized technical capabilities, exemplified by the establishment of a clinical molecular testing laboratory in Uruguay [14][15] Group 4: Future Directions - The gene testing industry is expected to see a normalization of health management, with gene data becoming a fundamental element of personal health records as sequencing costs decrease [16] - The rise of the bio-manufacturing industry will require precise analysis of life systems, with gene sequencing providing essential data support [16] - The company's goal is to make gene testing a routine, accessible tool for everyone, moving it from a specialized service to a common health resource [16]

国浩律师（深圳）事务所 关于 深圳华大基因股份有限公司 二〇二六年第一次临时股东会 之 法律意见书 广东省深圳市福田区深南大道 6008 号特区报业大厦 42、41、31DE、2403、2405，邮编：518034 42、41、31DE、2403、2405, Tequbaoye Building 6008 Shennan Avenue Shenzhen 518034, China 电话/Tel: +86 755 83515666 传真/Fax: +86 755 83515333 网址/Website: http://www.grandall.com.cn 二〇二六年二月 根据相关法律法规的要求，按照律师行业公认的业务标准、道德规范和勤勉 1 深圳华大基因股份有限公司 2026 年第一次临时股东会法律意见书 国浩律师（深圳）事务所 关于深圳华大基因股份有限公司 二〇二六年第一次临时股东会之 法律意见书 编号：GLG/SZ/A2626/FY/2026-084 号 致：深圳华大基因股份有限公司 国浩律师（深圳）事务所（以下简称本所）接受深圳华大基因股份有限公司 （以下简称公司、贵公司）委托，指派本所律师出席公司 2 ...